

DAFTAR PUSTAKA

- Ahmad A. 2013. Pathways to Breast Cancer Recurrence. *ISRN Oncology*
- Alitao K, Carmeliet P. 2002. Molecular mechanisms of lymphangiogenesis in health and disease. *Cancer Cell*,1:219-27
- Allison KH. 2012. Molecular Pathology of breast cancer. *American Journal of Clinical Pathology*,138:770-780
- Al-Rawi MAA, Mansel RE, Jiang WG. 2005. Molecular and cellular mechanisms of lymphangiogenesis. *The Journal of Cancer Surgery*,31:117-121.
- Al-Sarireh, B.; Eremin, O. 2000. Tumor associated macrophages: disordered function, immune suppression and progressive tumour growth. *Surgeon-Journal of the Royal Colleges of Surgeons of Edinburg and Ireland*, 45:1-16
- Althuis MD, Fergenbaum JH, Garcia-Closas M, Brinton LA, Madigan MP, Sherman ME. 2004. Etiology of hormone receptor-defined breast cancer: A systematic review of the literature. *Cancer Epidemiology Biomarkers and Prevention*,13(10):1558-68
- Arnaout-Alkarain A, Kahn HJ, Narod SA, Sun PA, Marks AN. 2007. Significance of lymph vessel invasion identified by the endothelial lymphatic marker D2-40 in node negative breast cancer. *Modern Pathology*,20(2):183-91
- Aryandono T. 1999 *Perkembangan mutakhir penatalaksanaan kanker payudara. Kumpulan makalah seminar kursus penyegar perkembangan mutakhir penatalaksanaan penyakit kanker*, Yogyakarta, 15-16 Maret
- Aryandono T, Harijadi, Ghozali A. 2000, Correlation of clinical, pathological status, hormone receptor and C-erbB-2 oncoprotein in breast cancer patients, *Gan To Kagaku Ryoho*, 27 Suppl 2:600-6
- Bando H, Weich HA, Horiguchi S, Funata N, Ogawa T and Toi M. 2006. The association between vascular endothelial growth factor, its corresponding receptor, VEGFR-3, and prognosis in primary breast cancer. A study with 193 cases. *Oncology Report*, 15:653-659
- Banerjee S, Dowsett M, Asworth A, Martin L. 2007. Mechanisms of disease: angiogenesis and the management of breast cancer. *Nature Review Clinical Oncology*,4:536-50
- Barkan D, Chambers AF. 2011. beta1-integrin: a potential therapeutic target in the battle against cancer recurrence. *Clinical Cancer Research*, 17:7219-7223
- Beasley NJP, Prevo R, Banerji S. *et al.*, 2002. Intratumoral lymphangiogenesis and lymph node metastasis in head and neck cancer, *Cancer Research*,62:1315-20

- Birner P, Schindl M, Obermair A, breitenecker G, Kowalski H, Oberhuber G. 2001. Lymphatic microvessels density as a novel prognostic factor in early-stage invasive cervical cancer. *International Journal of Cancer*,95:29-33
- Blackwell KL, Dewhirst MW, Liotcheva V, Snyder S, Broadwater G, Bently R, Lal A, Riggins G, Anderson S, Vredenburg J, Proia A, Harris LN. 2004. Her-2 gene amplification correlates with higher levels of angiogenesis and lower levels of hypoxia in primary breast tumors. *Clinical Cancer Research*, 10:4083-8
- Blows FM, Driver KE, Schmidt MK, Broeks A, van Leeuwen FE, Wesseling J, Cheang MC, Gelmon K, Nielsen TO, Blomqvist C, Heikkila P, Heikkinen T, Nevanlinna H, Aksien LA, Olson JE, Baglietto L, Giles G, Severi G, McLean CA, Southey MC, Rakha E, Green AR, Ellis IO, Lissowska J, Anderson WF, Cox A, Cross AM, Reed MWR, Easton DF, Garcia-Closas M, Caidas C, Pharoah PD, Huntsman D. 2010. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: A collaborative analysis of data for 10,159 cases from 12 studies. *Plos Medicine*,7(5):e1000279
- Borello AE, Martin C, Basquiera AL, Riva P, Calafat P, Diller A, Palazzo E, Garcia JJ. 2011. *Journal of Clinical Oncology* 29: (suppl; abstr e21037)
- Botting SK, Fouad H, Elwell K, Rampy BA, Salama SA, Freeman DH, Diaz-Arrastia CR. 2010. Prognostic significance of peritumoral lymphatic vessels density and vascular endothelial growth factor receptor-3 in invasive squamous cell cervical cancer. *Translational Oncology*,3(3):170-5
- Bottini A, Berruti A, Bersiaga A. et al., 2001. Relationship between tumor shrinkage and reduction in Ki-67 expression after primary chemotherapy in human breast cancer. *British Journal of Cancer*,85:1106-12
- Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V.2007 Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California Cancer Registry. *Cancer*. 109:1721–1728.
- Brewster AM, Chavez-MacGregor M, Brown P. 2014. Epidemiology, biology and treatment of triple-negative breast cancer in women of African ancestry. *Lancet Oncology*,15(13):e625-e634
- Brown JM. 2000. Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies. *Molecular Medicine Today*, 6:157-62
- Brown DC dan Gatter KC. 2002. Ki-67 protein: The immaculate deception? *Histopathology*, 40:2-11
- Bultitude MF, Fentiman IS. 2002. Breast cancer in older women. *International Journal of Clinical Practice* . 56:588-90

- Burke HB, Hutter RVP, Henson DE. 1995. Breast cancer. Dalam: Hermanek P, Gospodarowicz MK, Henson DE, Hutter RVP, Sobin LH (eds). *Prognostic factors in cancer*. Springer, Berlin:165-73
- Cabioglu N, Yazici MS, Arun B, Broglio KR, Hortobagyi GN, Price JE, Sahin A. 2005. CCR 7 and CXCR 4 as novel biomarkers predicting axillary lymph node metastasis in T1 breast cancer. *Clinical Cancer Research*,11:5686-93
- Carey LA, Perou CM, Livasy CA, et al., 2006. Breast cancer sub-types, and survival in the Carolina Breast Cancer Study. *Journal of the American Medical Association*.295(21):2492-2506
- Calore EE, Manzione CR, Nadal SR, Cavalieri MJ, Calore NMP, dos Santos R. P. 2001. Ki-67 expression in anal intraepithelial neoplasia in AIDS. *Sao Paulo Medical Journal*,1119:3
- Campbell MJ, Tonlaar NY, Garwood ER, Huo D, Moore DH, Kharmtsov AL, Baehner AF, Chen Y, Malaka DO, Adeyanju AO, Li S, Gong C, Olopade MO, Esserman LJ. 2011. Proliferating macrophages associated with high grade, hormone receptor negative breast cancer and poor clinical outcome. *Breast Cancer Research and Treatment*, 128:703-11
- Canello G, Maisonneuve P, Rotmensz N, Viale G, Mastropasqua MG, Pruneri G, Montagna E, Iorfida M, Mazza M, Balduzzi A, Veronesi P, Luini A, Intra M, Goldhirsch A, Colleoni M. 2012. Progesterone receptor loss identifies Luminal B breast cancer subgroups at higher risk of relapse. *Annals of Oncology*, 00: 1–8
- Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karac G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC, 2006. Race: Breast cancer subtypes, and survival in the Carolina Breast Cancer study. *Journal of the American Medical Association*,295:2492-2505
- Carney WP, Litzel K, Ali S, Neumann R, Lipton A. 2007 HER-2/neu diagnostics in breast cancer. *Breast Cancer Research*,9:1-11
- Chang JC, Hilsenbeck G. 2010. Prognostic and predictive factors. Dalam: Harris JR, Lippmann ME, Morrow M, Osborne CK (ed). *Disease of the breast*, 2nd, ed. Lippincott, Williams and Wilkins, Philadelphia:443-57
- Chanrion M, Fontaine H, Rodriguez C, Negree V, Bibeau F, Theillet C, Henaut A, Darbon JM. 2007. A new molecular breast cancer subclass defined from a large scale real-time quantitative RT-PCR study. *BioMed Central Cancer*,7(39): 2407
- Cheang MC, Treaba DO, Speers CH, Olivoto IA, Bajdick CD, Chia SK, Glodstein LC, Gelmon KA, Huntsman D, Gilks CB, Nielsen TO, Gown AM. 2006. Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival. *Journal of Clinical Oncology*,24:5637-44

- Cheang MCU, Chia SK, Voduc D, Gao D, Leung SL, Snider J, Watson M, Davies S, Bernard PS, Parker JS, Perou CM, Ellis MJ. 2009. Ki-67 indeks, Her-2 status and prognosis of patients with luminal B breast cancer. *Journal Nationalof Cancer Institute*,101:736-50
- Cheang MC, Voduc D, Bajdic C, Leung S, Mc Kinney S, Chia SK, Perou CM, Nielsen TO. 2008. Basal-like breast cancer defined by five biomarkers has high prognostic value than triple-negative phenotype. *Clinical Cancer Research*.14(5):1368-76
- Chia SK, Speers CH, Bryce CJ, Hayes MM, Olivotto IA. 2004. Ten-year outcomes in a population-based cohort of node-negative, lymphatic, and vascular invasion-negative early breast cancers without adjuvant systemic therapies. *Journal of Clinical Oncology*. 22(9):1630–1637
- Chin S, Antoinette Green CM, Gordonstrachan GM, Frances Wharfe GH. 2014. Locally Advanced Breast Cancer in Jamaica: Prevalence, Disease Characteristics and Response to Preoperative Therapy. *Asian Pacific Journal of Cancer Prevention*, 15 (7): 3323-3326
- Christiansen JJ, Rajasekaran AK. 2006. Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. *Cancer Research*, 66(17) :8319–8326
- Chuthapisith S, Permsapaya, W, Warnnissorn M, et al, 2012. Breast cancer subtypes identified by the ER, PR and Her-2 status in Thai women. *Asian Pacific Journal of Cancer Prevention*, 13, 456-62
- Ciobanu M, Eremia IA, Craitoiu S, Margaritescu CH, STEPAN A, Patrascu V, Georgescu CC, Cernea D, Dumitrescu D. 2013. Lymphatic microvessels density, VEGF-C, and VEGFR-3 expression in 25 cases of breast invasive lobular carcinoma. *Rom Journal Morphology Embryology*, 54(4):925–934
- Clarijs, R., Schalkwijk, L., Hofmann, U. B., Reiter, D. J., de Waal, R. W. 2002 Induction of VEGFR expression on microvasculature as a new progression marker in human cutaneous melanoma. *Cancer Research*,62:7059-65
- Clarijs R, Ruiter DJ, e Waal RM. 2001. Lymphangiogenesis in malignant tumor. Does it occur? *Journal of Pathology*, 193: 143-6
- Clark GM, 2000. Prognostic and predictive factors. Dalam: Harris JR, Lippmann ME, Morrow M, Osborne CK (eds). *Disease of the breast*. 2nd, eds. Lippincott, Williams & Wilkins, Philadelphia:489-514
- Cleator S, Heller W, Coombes RC. 2007. Triple-negative breast cancer: therapeutic options. *Lancet Oncology*, 8: 235-44.
- Colditz GA, Rosner BA, Chen WY, Holmes MD, Hankinson SE. 2004. Risk factors for breast cancer according to estrogen and progesterone receptor status. *Journal of The National Cancer Institute*,96(4):218-28
- Collett K, Stefansson IM, Eide J, Braaten A, Wang H, Aude GE, Thoresen SQ, Foulkes WD, Akslen LA. 2005. A basal epithelial phenotype is more

- frequent in interval breast cancers compared with screen detected tumors. *Cancer Epidemiology Biomarkers Prevention* 14:1108-1112
- Colleman RE, Rubbens RD. 1987. The clinical course of bone metastasis. *British Journal of Cancer*. 55:61-6
- Comen EA, Norton L. 2011. Breast cancer tumor size, nodal status, prognosis: biology trumps anatomy. *Journal of Clinical Oncology*, 2619-28
- Cotran RS, Kumar V, Robbins T. 2005. *Robbins Pathologic Basis of Disease*, 6theds, W. B. Saunders Co. Philadelphia.
- Cunnick GH, Jiang WG, Douglas-Jones T, Watkins G, Gomez KF, Morgan MJ, Subramanian A, Mokbel K, Mansel RE. 2008. Lymphangiogenesis and lymph node metastasis in breast cancer. *Molecular Cancer*, 7(23):1-10.
- Dadiani M, Kalchenko V, Yosepovich A, Margalit R, Hassid Y, Degani H, Seger D. 2006. Real time imaging of lymphangiogenic metastasis in orthotopic human breast cancer. *Cancer Research*, 66:365-414
- Dabrosin C, 2005. Sex steroid regulation of angiogenesis in breast tissue. *Epub*, 8(2) 127-36
- Dalquen P, Baschiera B, Chaffard R, Dieterich H, Feichter GE, Kremer K, Torhorst J. 1997. MIB-1 (Ki-67) immunostaining of breast cancer cells in cytologic smear. *Acta Cytologica*, 41(2):229-237
- Davies EL, Sweetland HM 2010. Metastatic disease of the breast and local recurrence of breast cancer. *Surgery*, 28(3):144-7
- De Potter CR, 1994. The neu oncogene: more than a prognostic indicator? *Human Pathology*, 25:1264-8
- de Roos MA, de Bock GH, de Vries J, Wesseling J 2007. P53 overexpression is a predictor of local recurrence after treatment for both in situ and invasive ductal carcinoma of the breast. *Journal Surgical Research* 140:109-114
- De Vivo I, Hankinson SE, Colditz GA, Hunter DJ. 2004. The progesterone receptor Val660-Leu polymorphism and breast cancer risk. *Breast Cancer Research*, 6:R636-9
- Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA. 2007. Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence Rebecca. *Clinical Cancer Research*. 13(15):4429-4434
- Demetrius LA, Coy JF, Tuszynsky JA. 2010. Cancer proliferation and therapy: The Warburg effect and quantum metabolism. *Theoretical Biology and Medical Modelling* .7:2
- Dings PJ, Elferink MA, Strobbe LJ, de Wilt JH. 2013. The prognostic value of lymph node ratio in node-positive breast cancer: a Dutch nationwide population-based study. *Annals Surgical Oncology*, 20(8):2607-14

- Donegan WL. 1997. Tumor related prognostic factor for breast cancer. *Cancer Journal for Clinicians*, 47:28
- Dunnwald LK, Rossing MA, Li C. 2007. Hormone receptor status, tumor characteristics and prognosis: a prospective cohort of breast cancer patients. *Breast Cancer Research*, 9:1-10
- Edwards MJ, Bonadonna G, Valagussa P, *et al.*, 1998. End points in the analysis of breast cancer survival: Relaps versus death from tumor. *Surgery*, 124:197-2002
- Elder EE, Kennedy CW, Gluch L, Carmalt HL, Janu NC, Joseph MG, Donellan MJ, Molland JG, Gillett DJ. 2006. . Patterns of breast cancer relapse. *The Journal of Cancer Surgery*. 32 : 922e927
- El Fatemi H, Chahbouni S, Jayi S, *et al* (2012). Luminal B tumors are the most frequent molecular subtype in breast cancer of North African women: an immunohistochemical profile study from Morocco. *Diagnostic Pathology*, 7, 170-6
- El-Ghohary YM, Metwally G, Saad RS, Robinson MJ, Mesko T, Poppiti RJ. 2008. Prognostic significance of intratumoral and peritumoral lymphatic density and blood vessels density in invasive breast carcinoma. *American Journal of Clinical Pathology*, 129:578-86
- El-Hawary AK, Abbas AS, Elsyayed AA, Zalata KR (2012). Molecular subtypes of breast carcinoma in Egyptian women: Clinicopathological features. *Pathology-Research and Practice*, 208, 382-6.
- Elston CW, Ellis IO, 1991. Pathological prognostic factor. I. The value of histological grades in breast cancer. Experience from a large study with long-term follow-up. *Histopathology*, 19:403-10
- Engström MJ, Opdahl S, Hagen AI, Romundstad PR, Akslen LA, Haugen AO, Vatten LJ, Bofin AM. 2013. Molecular subtypes, histopathological grade and survival in a historic cohort of breast cancer patients. *Breast Cancer Research Treatment*, 140:463–473
- Erdem O, Dursun A, Coskun U, Gunel N. 2005. The prognostic value of p53 and c-erbB-2 expression, proliferative activity and angiogenesis in node-negative breast carcinoma. *Tumori*, 91:6-52
- Fasching PA, Heusinger K, Haeberle L, Niklos M, Hein A, Bayer CM, Rauh CM, Schulz-Wendtland R, Bani MR, Schrauder M, Kahmann L, Lux MP, Strehl JD, Hartmann A, Dimmler A, Beckmann MW, Wachte DL. 2011. Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment. *BioMed Central Cancer*. 11:486
- Filho AL, Martins A, Araujo Costa SM, Schmitt FC. 2005. VEGFR-3 expression in breast cancer tissue is not restricted to lymphatic vessels. *Pathology Research and Practice*, 201:93-9

- Fisher B, Jeong JH, Bryant J, Anderson S, Dignam J, Fisher ER, Wolmark N. 2004. Treatment of lymphnode negative, oestrogen-receptor positive breast cancer: long term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials. *Lancet* 364(9437):858-68
- Foulkes WD, Grainge MJ, Rakha EA, Green AR, Ellis EO. 2009. Tumor size is an reliable unpredictor in basal-like breast cancer and does not correlate closely with lymphnode status. *Breast Cancer Research and Treatment*, 117(1):199-204
- Freedman GM, Fowble ML. 2000. Local Recurrence After Mastectomy or Breast-Conserving Surgery and Radiation. *Oncology*, 14(11):1561-81
- Furudoi A, Tanaka S, Hamura K. et al., 2002. Clinical significance of VEGF-C and angiogenesis at the deepest invasive of advance colorectal carcinoma. *Oncology*, 62:157-66
- Fuji T, Otsuki T, Moriya T, Sakaguchi H, Kurebayashi J, Yata K. 2002. Effect of hypoxia on human seminoma cells. *International Journal of Oncology*, 20:955-62
- Galukande M, Wabinga H, Mirembe F, Karamagi C, Alexzander A. 2014. Molecular breast cancer subtypes prevalence in an indigenous Sub Saharan African population. *Pan African Medical Journal*. 17:249
- Ganapathy V, Banah-Petroschy W, Xie W, Karredula A, Nienhuis H, Miles, G, Reiss M. 2012. Luminal breast cancer metastasis is dependent on estrogen signaling. *Clinnical Experimental Metastasis*. 29(5)
- Gao X, Nawaz Z. 2004. Progesteron receptors-animal models and cell signaling in breast cancer: Role of steroid receptor coactivators and corepressors of progesterone receptors in breast cancer. *Breast Cancer Research*, 4:182-6
- Geho DH, Bandle RW, Clair T, Liotta LA. 2005. Physiological mechanisms of tumor – cell invasion and migration. *Physiology*, 20:194-200
- Gisterek I, Matkowski R, Kozlak J, Dus D, Lacko A, Stelachowska J, Kornafel J. 2007. Evaluation of prognostic value of VEGF-C and VEGF-D in breast cancer--10 years follow-up analysis. *Anticancer Research*. 27(4C):2797-802
- Gnant M, Harbeck N, Thomssen C. 2011. St. Gallen 2011: Summary of the consensus discussion. *Breast Care*, 6:136-41
- Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thurlimann B, Senn HJ 2005. Meeting highlights: International expert consensus on the primary therapy of early breast cancer. *Annals of Oncology* , 16:1569-83
- Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ. 2011. Strategies for subtypes-dealing with the diversity of breast cancer: Highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. *Annals of Oncology Advanced Access, Published June 2011*.

- Goss PE, Chambers AF. 2010. Does tumour dormancy offer a therapeutic target? *Nature Reviews Cancer*.10(12): 871–877
- Gottlinger HG, Rieber P, Gpkel JM, Lohe KJ, Reithmuller G. 1985. Infiltrating mononuclear cells in human breast carcinoma: predominance of T4+ monocytic cells in the tumor stroma. *International Journal of Cancer*,35:199-205
- Gunningham SP, Currie MJ, Han C, Robinson BA, Scott PA, Harris AL, Fox SB. 2000. The short form of the alternatively spliced flt-4 but not its ligand vascular endothelial growth factor C is related to lymph node metastasis in human breast cancers. *Clinical Cancer Research*. 6(11):4278–4286
- Gurleyik G, Gurleyik E, Aker F et al., 2007. Lymphovascular invasion as a prognostic marker in patients with invasive breast cancer. *Acta Chirurgica Belgica*, 107(3):284-7
- Haffy BG, Yang Q, Reiss M, Kearney T, Higgins SA, Weidhass J, Harris L, Hait W, Toppmeyer D. 2006. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. *Journal of Clinical Oncology*, 24:5652–5657.
- Hagiwara Y, Sunada Y. 2007. Mechanism of Taxanes neurotoxicity. *Breast Cancer*,11(1):82-85
- Hammond EH, Hayes DF, Wolff AC, Mangu PB, Temin S. 2010. American Society of Clinical / College of American Pathologists Guideline Recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. *Journal of Oncology Practice*, 6(4):195-7
- Harrel JC, Dye WW, Allred C, Jedlicka P, Spoelstra NS, Sartorius CA, Horwitz KB. 2006 Estrogen receptor positive breast cancer metastasis: Altered hormonal sensitivity and tumor aggressiveness in lymphatic vessels and lymph nodes. *Cancer Research*,66(18):9308-15
- Hawland NK, Driver TD, Sedrak MP, Wen X, Dong W, Hatch S, Eltorky MA, Chao C. 2013. Lymphnodeinvolment in immunohistochemistry-based molecular classification of breast cancers.*Journal of Surgical Research*, 185:697-703
- Heaphy CM, Subhawong AP, GrossAL, Konishi Y, Kouprina N, ArganiP, VisvanathanK, and Meeker AK. 2011. Shorter telomeres in luminal B, HER-2 and triple-negative breast cancer subtypes. *Modern Pathology*, 24: 194–200
- Hirakawa S, Brown LF, Kodama S, Paavonen K, Alitalo K, Detmar M. 2007. VEGF-C induced lymphangiogenesis in sentinel lymph node promotes tumor metastasis to distant site. *Blood*, 109(3): 1010-1017

- Hoar FJ, Chaudhri S, Wadley MS, Stonelake PS. 2003. Co-expression of vascular endothelial growth factor-C and c-erbB-2 in human breast carcinoma. *European Journal of Cancer*, 39:1698-1703
- Huang WY, Newman B, Milikan RC, Schell MJ, Hulka BS, Moorman PG. 2000. Hormone-related factors and risk of breast cancer in relation to ER and PR status. *American Journal of Epidemiology*, 151:703-14
- Hyder SM, Stancel GM. 1999. Regulation of Angiogenic Growth Factors in the Female Reproductive Tract by Estrogens and Progestins. *Molecular Endocrinology*, 13(6):806-11
- Hyder SM. 2006. Sex steroid regulation of VEGF in breast cancer. *Endocrine Related Cancer*, 13:667-87
- Huges DC. 2001. Alternative splicing of the human VEGFR-3/FLT4 gene as a consequence of an integrated human endogenous retrovirus. *Journal of Molecular Evolution*. 53:77-9
- Ibrahim E, Al-Gahmi AM, Zeeneldin AA, Zekri J, Elkhodary T, Gaballa HE. 2008. Basal vs. luminal A breast cancer subtypes: a matched case-control study using estrogen receptor, progesterone receptor, and HER-2 as surrogate markers. *Medical Oncology*, 26(3):372-8
- Jackson DG. 2003. The lymphatics revisited: new perspectives from the hyaluronan receptor LYVE-1. *Trends Cardiovascular Medicine*, 13-7
- Jacobs TW, Gown AM, Yaziji H, Barnes MJ, Schnitt SJ. 2000. HER-2/neu protein expression in breast cancer evaluated by immunohistochemistry. *American Journal of Pathology*, 113:251-8
- Jager JJ, Jansen RL, Arends JW, Joosten-Achjanie S, Volovics L, Schouten LJ. 2000. Antiapoptotic phenotype is associated with decreased locoregional recurrence rate in breast cancer. *Anticancer Research*, 20:1269-1275, 2000
- Jans BJ, Escudero MN, Pulgar BD, Acevedo CF, Sanchez RC, Camus AM. 2014. Clinicopathologic subtypes and compromise of lymph nodes in patients with breast cancer. *Ecancer*, 8:448-57
- Jayasinghe C, Simiantonaki N, Michel-Schmidt R, Kirkpatrick CJ. 2009. Endothelial VEGFR-3 expression in colorectal carcinoma is associated with hematogenous metastasis. *Oncology Report*, 22:1093-1100
- Jenkins EO, Deal AM, Anders CK, Perou CM, Carey LA, Muss HB. 2014. Age-Specific Changes in Intrinsic Breast Cancer Subtypes: A Focus on Older Women. *The Oncologist*, 19:1076-1083
- Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. 2003. Cancer statistic, 2003. *Cancer Journal for Clinicians*, 53:5-26
- Joensuu H, Isola J, Lundin M, Salminen T, Holli K, Kataja V, Pylkkänen L, Turpeenniemi-Hujanen T, von Smitten K, Lundin J. 2003. Amplification of erbB2 and erbB2 expression are superior to estrogen status as risk factors

- fpr distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study. *Clinical Cancer Research*, 9(3):923-30.
- Jordan VC. 2006. Tamoxifen as a targeted therapy to treat and prevent breast cancer. *British Journal of Pharmacology*. **147** (Suppl 1): S269–76
- Joukov V, Kumar V, Sorsa T, Arighi E, Weich H, Saksela O and Alitalo K. 1998. *Journal of Biological Chemistry*. 273, 6599–6602
- Kalra VK, Shen Y, Sultana C, Rattan V. 1996. Hypoxia induces PECAM-1 phosphorylation and transendothelial migration of monocytes. *American Journal of Physiology*, 27:H2025-34
- Kamby C, Ejlersen B, Andersen J. et al., 1988. The pattern of metastasis in human breast cancer. Influence of systemic adjuvant therapy and impact on survival. *Acta Oncologica*, 27:715-9
- Kao J, Salari K, Bocanegara M, Choi YL, Girard L, Kwei KA, Hernandez-Boussard T, Wang P, Gadzar AF, Minna JD, Pollack JR. 2009. Molecular profiling of breast cancer cell defines relevant tumor models and provides a resource for cancer gene discovery. *PloS One*, 4(7):e6146, doi:10.1371
- Kadivar M, Mafi N, Joulaee A, et al (2012). Breast cancer molecular subtypes and association with clinicopathological characteristics in Iranian women, 2002-2011. *Asian Pacific Journal of Cancer Prevention*. 13, 1881-6
- Karkkainen MJ, Haiko P, Sainio K. et al., 2004. VEGF-C is required for sprouting of the first lymphatic vessels from embryonic veins. *Natural Immunology*, 5:74-80
- Ke Q, Costa M. 2006. Hypoxia-inducible Factor-1 (HIF1). *Molecular Pharmacology*, 70(5): 1469-1480
- Kennecke H, Yerushalmi R, Woods R, Chon M, Voduc D, Speers CH, Nielson TO, Gelmon K. 2010. Metastatic behaviour of breast cancer subtypes. *Journal of Clinical Oncology*, 28:3271-3277
- Kinane DW. 1991. Staging and follow-up of breast cancer patients. *Cancer*, 18:1196-8
- Kinoshita J, Kitamura K, Kabashima A, Saeki H, Tanaka S, Sugimachi K. 2001. Clinical significance of vascular endothelial growth factors-C in breast cancer. *Breast Cancer Research and Treatment*, 66:159-64
- Kim HS, Park I, Cho HJ, Gwak G, Yang K, Bae BN, Kim KW, Han S, Kim HJ, Kim YD. 2012. Analysis of the Potent Prognostic Factors in Luminal-Type Breast Cancer. *Journal of Breast Cancer*, 15 (\$): 401-6.
- Kitano H, Kageyama S, Hewitt SM, Hayashi R, Doki Y, Ozaki Y, Fujino S, Takikita M, Kubo H, Kukuoka J. 2010. Podoplanin expression in cancerous stroma induces lymphangiogenesis and predicts lymphatic spread and patient survival. *Archives of Pathology and Laboratory Medicine*, 134:1520-7

- Koenders PG, Beex LV, Langens R, Kloppenborg PW, Smals AG, Benraad TJ. 1991. Steroid hormone receptor activity of primary human breast cancer and pattern of first metastasis. The Breast Cancer Study Group. *Breast Cancer Research and Treatment*. 18:27–32
- Kohail HM, Elias EG, el-Nowiem SA, Bashirelahi N, Didolkar MS, Reed WP. 1985. A multifactorial analysis of steroid hormone receptors in stage I and II breast cancer. *Annals Surgery*, 201:611-7
- Khokher S, Qureshi MU, Mahmood S, Nagi AH (2013). Association of immunohistochemically defined molecular subtypes with clinical response to presurgical chemotherapy in patients with advanced breast cancer. *Asian Pacific Journal of Cancer Prevention*. 14, 3223-28
- Krizmanich-Conniff K, Paramagul C, Petterson S, Helvie MA, Roubidoux MA. Myles JD, Jian Q, Sabel M. 2012. Triple negative breast cancer: Imaging and clinical characteristic. *American Journal of Rontgenology*, 199(2):458-464.
- Kumar V, Abbas AK, Fausto N, Aster JC. 2010. *Robbins and Cotran, Pathologic Basis of Disease*. 8th eds, Elsevier Saunders
- Lacapelle J dan Foulkes WD. 2011. Triple negative and basal-like breast cancer: Implication for oncologist. *Current Oncology*, 18(4): 161–164.
- Lee MC, Newman LA. 2007. Management of Patients with Locally Advanced Breast Cancer. *Surgical Clinical of North America*, 87: 379–398
- Lemeshow S, Hosmer Jr DW, Klar J, Lwanga SK. 1990. *Besar sampel dalam penelitian Kesehatan*. Gadjah Mada University Press, Yogyakarta
- Levine MN, Whelan T. 2006. Adjuvant chemotherapy for breast cancer- 30 years later. *The New England Journal of Medicine*, 355:1920-22
- Liang X, Yang D, Hu J, Hao X, Gao J, Mao Z. 2008. Hypoxia inducible factor-1 alpha expression correlates with vascular endothelial growth factor-C expression and lymphangiogenesis/ angiogenesis in oral squamous cell carcinoma. *Anticancer Research*, 28:1659-66
- Liao GS, Chou YC, Hsu HM, Dai MS, Yu JC. 2014. The prognostic value of lymph node status among breast cancer subtypes. *The American Journal of Surgery*. doi:10.1016/ j.amjsurg.2014.05.029
- Linboe CF, Torp SH. 2002. Comparison of Ki-67 equivalent antibodies. *Journal of Clinical Pathology*, 55:467-71
- Li R, Younes M, Wheeler TM, Scardino P, Ohori M, Frolov A, Ayala G. 2004. Expression of VEGFR-3 in human prostate, *Prostate*, 58:193-9
- Li ZS, Yao L, QuYang T, Li JF, Wang TF, Fan ZQ, Fan T, Lin BY, Xie YT. 2011. Breast cancer subtypes and survival in Chinese women with operable primary breast cancer. *Chinese Journal Cancer Research*, 23(2):134-139

- Lin YC, Chen SC, Chang HK, Hsueh S, Tsai CS, Lo YF, Hwang TL, Chen MF. 2005. Identifying good prognosis of breast cancer patients with 1-3 positive axillary nodes for adjuvant cyclophosphamide, methotrexate and 5-fluouracil (CMF) chemotherapy. *Japan Journal of Clinical Oncology*, 35(9):514-9
- Lin Y, Yin W, Zhou L, Di G, Wu J, Shen Z, Shaou Z, Lu J. 2009. Site-specific relapse pattern of the triple negative tumors in Chinese breast cancer patients. *BioMed Central*, 9:342
- Lippman ME, Dickson RB. 1989. Mechanism of normal and malignant breast epithelial growth regulation. *Journal of Steroid Biochemistry*, 34: 107-21
- Liu SL, Clouthier SG, Wicha MS. 2012. Role of micro-RNA in the regulation of breast cancer stem cells. *Journal of Mammary Gland Biology and Neoplasia*, 17: 15-21
- Liu SL, Cong Y, Wang D, Sun Y, Deng L, Liu Y, Martin-Trevino R, Shang L, McDermott SP, Landis ML, Hong SY, Adams A, A"Angelo R, Wong ST, Zhan M, Chang JC, Wicha MS. 2014. Breast cancer stem cells transition between epithelial and mesenchymal states reflective of their normal counterparts. *Stem cell Reports*, 2:78-91
- Lohr, HA, van der Loos CM, Teeling P, Gown AM. 1999. Complete chromogenic separation and analysis in double immunohistochemical stains using photoshop-based image analysis. *Journal of Histochem Cytochem*, 47:119-25
- Lupu R, Cardilo M, Harris L et al., 1995. Interaction between ERB-receptors and heregulin in breast cancer tumor progression and drug resistance. *Seminars in Cancer Biology*, 6:135-45
- Ma H, Wang Y, Sullivan-Halley J, Weiss L, Burkman RT, Simon MS, Malone KE, Strom BL, Ursin G, Press MF, Bernstein L. 2009. Breast cancer receptor status: Do result from a centralized pathology laboratory agree with SEER registry reports? *Cancer Epidemiology Biomarkers and Prevention*, 18(8):2214-20
- Makinen T, Veikkola T, Mustjoki S, Karpanen T, Catimel B, Nice EC, Wise L, Mercer A, Kowalski H, Kerjaschki D, Stacker SA, Achen MG, Alitalo K. 2001. Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3. *The EMBO Journal*. 20(17): 4762-73
- Masood S. 2005. Prognostic/predictive factors in breast cancer. *Clinical Laboratory Medicine*. 25(4):809-25
- Marson, L. P., Kurian, K. M., Miller, W. R., Dixon, J. M. 2001. The effect of tamoxifen on breast tumour vascularity. *Breast Cancer*, 66:9-15

- Marinho VFZ, Metze K, Sanches FS, Rocha GFS, Gobbi H. 2008 Lymph vascular invasion in invasive mammary carcinomas indentified by the endothelial lymphatic marker D2-40 is associated with other indications of poor prognosis. *BioMed Center Cancer*,8:64
- Matilla MMT, Ruohola JK, Karpanen T, Jackson DG, Alitalo K, Harkonen PL. 2002.VEGF-C induced lymphangiogenesis is associated with lymph node metastasis in orthotopic MCF-7 tumors. *International Journal of Cancer*. 98:946-951
- Matsumoto, K. 1978 Progesterone and estrogen receptor in jaanesebrast cancer, In:*Hormones, receptors and breast cancer*. McGuire W. L. (ed). Raven Press, New York,43-58
- Meyer JS. 1998. Cell kinetics of breast and breast tumor, Dalam: Donegan, W. L., Sprat, J. S. (eds). *Cancer of the breast* . WB Saunders, Philadelphia:279-308
- McArthur HL, Hudis CA. 2007. Adjuvan therapy for early-staged breast cancer.*Hematology/ Oncology Cliic ofn North America*.21: 207-22
- McCormick D, Chong H, Hobbs C, et al. 1993. Detection of the Ki-67 antigen in fixed and wax emedded sections with the monoclonal antibody Mib1.*Histopathology*,22:355-60
- McDermott SP, Wicha MS. 2010. Targeting breast cancer stem cells.*MolecularOncology*, 4(5): 404–419
- McShane LM, Altman DG, Sauerbrei W. et a., 2005. Reporting recomendations for tumor marker prognostic studies (REMARK). *National Journal of Cancer Institute*, 97(16):1180
- Millikanen RC, Newman B, Tse CK, Moorman PG, Conway K, Dressler LG, Smith LV, Labbok MH, Geradts J, Bensen JT, Jackson S, Nyante S, Livasy C, Carey L, Earp HS, Perou CM. 2008. Epidemiology of basal-like breast cancer. *Breast Cancer Research Treatment*. 109(1):123-39
- Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. 2004.Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. *Pharmacological Reviews*. 56 (2): 185–229
- Mohammed KM, Le A, Duong H, Wu Y, Zhang Q, Messadi DV. 2004. Correlation between VEGF and HIF-1 alpha expression in human oral squamous cell carcinoma. *Experimental and Molecular Pathology*,76:143-53
- Mohammadizadeh F, Naimi A, Rajabi P, Ghasemibasir H, Eftekhari A. 2009. Expression of basal and luminal cytokeakins in breast cancer and their correlation with clinicopathological prognostic variables, *Indian Journal ofMedical Sciences*, 63(4):152-62

- Mokbel K. 2002. The evolving role of Aromatase Inhibitor in breast cancer. *International Journal of Clinical Oncology*. 7 (5): 279–83.
- Muhammed RAA, Green A, El-Shikh S, Paish EC, Ellis IQ, Martin SG. 2007. Prognostic significance of vascular endothelial cell growth factors -A, -C and -D in breast cancer and their relationship with angio- and lymphangiogenesis. *British Journal of Cancer*, 96:1092-1100
- Mukherjee D, Zhao J. 2013. The role of chemokine receptor CXCR4 in breast cancer metastasis. *American Journal of Cancer Research*, 3(1):46-57
- Mylona E, Alexandrou P, Mpkali A, Giannopoulou I, Liapis G, Markaki S, Keramopoulos A, Nakopoulou L. 2006. Clinicopathological and prognostic significance of vascular endothelial growth factors (VEGF)-C and -D and VEGF receptor 3 in invasive breast carcinoma. *The Journal of Cancer Surgery*, 33: 294-300
- Nakamura Y, Yasuoka H, Tsujimoto M, Yang Q, Tsukiyama A, Imabun S, Nakahara M, Nakao K, Nakamura M, Mori I, Kakudo K. 2003. Clinicopathological significance of VEGF-C in breast carcinoma with long-term follow-up. *Modern Pathology*, 16(4):309-14
- Nakamura Y, Yasuoka H, Tsujimoto M, Imabun S, Nakahara M, Nakao K, Nakamura M, Mori I, Kakudo K. 2005. Lymph vessel density correlates with nodal status, VEGF-C expression, and prognosis in breast cancer. *Breast Cancer Research Treatment*. 91(2):125–132.
- Nakopoulou LL, Alexiadou A, Theodoropoulos GE, Lazaris ACH, Tzonou A, Keramopoulos A. 1996. Prognostic significance of the co-expression of p53 and c-erbB-2 in breast cancer. *Journal of Pathology*, 179:31-8
- Najafi B, Anvari S, Roshan ZA, 2013. Disease free survival among molecular subtypes of early stage breast cancer between 2001 and 2002 in Iran. *Asian Pacific Journal of Cancer Prevention*, 14, 581-16
- Nathanson SD, Zarbo RD, Wachna L, Spence CA, Andrzejewski TA, Abrams J. 2000. Microvessels that predict axillary lymphnode metastasis in patients with breast cancer. *Archives Surgery*, 135:586-94
- Nathanson SD, Slater R, DeBruyn D, Kapke A, Linden MD. 2006. Her-2/neu expression in primary breast cancer with sentinel lymph node metastasis. *Annals Surgical Oncology*, 13:1-20
- Niakosari F, Kahn HJ, Marks A, From L. 2005. Detection of lymphatic invasion in primary melanoma with monoclonal antibody D2-40: a new selective immunohistochemical marker of lymphatic endothelium. *Archives of Dermatology*, 141:440-4
- Nguyen PL, Taghian AG, Katz MS, Niemierko A, Abi Raad RF, Boon WL, Bellon JR, Wong JS, Smith BL, Harris JR. 2000. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is

associated with local and distant recurrence after breast-conserving therapy. *Journal of Clinical Oncology*, 26:2373–2378.

O'Brian KM, Cole SR, Tse CK, Perou CM, Carey LA, Foulkes WD, Dressler LG, Geradts J, Millikan RC. 2010. Intrinsic breast cancer subtypes race and longterm survival in The Caroline Breast Cancer Study. *Clinical Cancer Research*.16(24):6100-10

Ogawa E, Takenaka K, Yanagihara K, Kurozumi M, Manabe T, Wada H, Tanaka F. Clinical significance of VEGF-C status in tumour cells and stromal macrophages in non-small cell lung cancer patients. *British Journal of Cancer*. 2004;91:498–503.

Okada K, Osaki M, Araki K, Ishiguro K, Ito H, Ohgi S. 2005. Expression of HIF-1 α , VEGF-C and VEGF-D in non – invasive and invasive breast ductal carcinomas. *Anticancer Research*,25:3003-10

Onitilo AA, Enget JM, Greenlee RT, Mukesh BN, 2008. Breast cancer subtypes based on ER/PR and HER-2/neu expression: Comparison of clinicopathologic features and survival. *Clinical Medicine & Research*,7(1/2):4-13

Oqba N, Manning NG, Bliesner BS, Ambler SK, Haughian JM, Pinto MP, Jedlicka P, Joensuu K, Heikkila P, Horwitz KB. 2014. Luminal breast cancer metastases and tumor arousal from dormancy are promoted by direct actions of estradiol and progesterone on the malignant cells. *Breast Cancer Res*. 2014; 16(6): 489.

Osteen RT, Karnell LH. 1994. The National Cancer Data Base Report on breast cancer. *Cancer*. 73:1994–2000

Ovcaricek T, Frkovic SG, Matos E, Mozina B, Borstnar S. 2011. Triple negative breast cancer – prognostic factors and survival. *RadiologyOncology*, 45(1): 46-52.

Padera TP, Kadambi A, Tomoso E. 2002. Lymphatic metastasis in the absence of functional intra tumor lymphatics. *Science*, 296:1883-1886

PanopoulosCG, Tzavara C, Papadimitriou K, Pistalmatzian N, Lypas G, Barbounis V, Demiri S, Koumakis G, Apostolikas N, Efremidis A. 2009. Relationship between lymphovascular invasion (LVI) and prognostic markers in different subtypes of breast cancer. *Journal of Clinical Oncology*27

Papper M. S. 2001. Lymphangiogenesis and tumor metastasis: myth or reality? *Clinical Cancer Research*. 7:462-8

Parise CA, Bauer KR, Caggiano V. 2010. Variation in breast cancer subtypes with age and race/ethnicity. *Critical Reviews in Oncology/Hematology* 76: 44–52

Parise CA, Caggiano V. 2014. Breast Cancer Survival Defined by the ER/PR/HER2 Subtypes and a Surrogate Classification according to tumor grade and immunohistochemical biomarker. *Journal of Cancer Epidemiology*, 2014, Article ID 469251, 11 pages

- Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, *et al.*, 2000. Molecular portraits of human breast tumours. *Nature*, 406:747-52
- Petit T, Wilt M, Velten M, Millon R, Rodier JF, Borel C, Mors R, Haeghele P, Eber M, Ghnassia JP. 2003. Comparative value of tumor grade, hormonal receptors, Ki-67, Her-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-nased chemotherapy. *European Journal of Cancer*, 40:205-11
- Polk HC, Gardner B, Stone H. 1993. *Basic Surgery* 4th eds. St Louis Missouri: Quality Medical Publishing Inc.
- Pujol P, Daures JP, Thezenas S. *Et al* 1998, Changing estrogen and progesterone receptor patterns in breast carcinoma during the menstrual cycle and menopause. *Cancer* 83:698-705
- Puti TC, El-Rehim DM, Rakha EA, Paish CE, Lee AH, Pinder SE, Ellis IO. 2000. Estrogen receptor-negative breast carcinomas: a review of morphology and immunophenotypical analysis. *Modern Pathology*, 18:1826-35
- Raica M, Cimpean AM, Ceausu R, Ribatti D. 2011. Lymphatic microvessel density, VEGF-C and VEGFR-3 expression in different molecular types of breast cancer. *Anti Cancer Research*, 31(5):1757-64
- Rahman ML, Deleyrolle V, Vedam-Mai, HA, Abdel-Barr M, Reynolds BA. 2011. The cancer stem cell hypothesis: failures and pitfalls. *Neurosurgery*, 68(2):531-545
- Ran S, Volk L, Hall K, Flister MJ. 2010. Lymphangiogenesis and lymphatic metastasis in breast cancer. *Pathophysiology*, 17(4):229-251
- Reed W, Hannisdal E, Boehler PJ, Gundersen S, Host H, Nesland JM. 2000. The prognostic value of p53 and c-erbB-2 immunostaining is overrated for patients with lymph node negative breast carcinoma. A multivariate analysis of prognostic factors in 613 patients with a follow-up of 14-30 years. *Cancer*, 88:804-13
- Reyal F, Rouzier R, Depont-Hazelt B, Bollet MA, Pierga J, Alran S, Salmon RJ, Fourchotte V, Vincent-Solomon A, Sastre-Garau X, Uzan S, Sigal-Zafrani B, De Rycke Y. 2011. The Molecular Subtype Classification is a determinant of sentinel node positivity in early breast carcinoma. *Plos One*. 6: e20297
- Rocheffort H, Glondou M, Sahla ME, Platet N, Garcia M. 2003. How to target estrogen receptor-negative breast cancer? *Endocrine-Related Cancer*, 10:261-6
- Rodríguez-Pinilla SM, Sarrió D, Honrado E, Hardisson D, Calero F, Benitez J, Palacios J. 2006. Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas. *Clinical Cancer Research*. 12(5):1533-9.
- Rosai J. 2004. *Rosai and Ackerman's Surgical pathology*, 9th eds, Mosby Toronto

- Rosen PP, Lesser ML, Arroyo CD, Cranor M, Borgen P, Norton L. 1995. Immunohistochemical detection of Her2/neu in patients with axillary lymph node negative breast carcinoma. A study epidemiologic risk factor, histology features and prognosis. *Cancer*,75:1320-6
- Rosen PP. 2009. *Rosen's Breast Pathology*, 3rdeds, Wolters Kluwer, Lippincott Williams & Wilkins, Philadelphia
- Ross JS, Flecher JA. 1999. Her-2/neu (c-erbB-2) gene and protein in breast cancer. *Journal of Clinical Pathology*, 112(Suppl):53-67
- Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanili M, Anderson K, Hess KR, Stec J, Ayers M, Wagner P, Morandi P, Fan C, Rabiul I, Ross JS, Hortobagyi GN, Pusztai L. 2005. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. *Clinical Cancer Research*,11(16):5678-85
- Saaristo A, Partanen TA, Arola J, Jussila L, Hytonen M, Makitie A, Vento S, Kaipainen A, Marnberg H, Alitalo A. 2000. VEGF-C and its receptor VEGFR-3 in the nasal mucosa and nasopharyngeal tumors. *American Journal of Pathology*,157(1):7-14
- Saimura M, Fukutomi T, Tsuda H, Sato H, Miyamoto K, Akashi-Tanaka S, Nanasawa T. 1999. Prognosis of series of 763 consecutive node-negative breast cancer patients without adjuvant therapy: analysis of clinicopathological prognostic factor. *Journal of Surgical Oncology*,71:101-5
- Salhia B, Tapia C, Ishak EA, Gaber S, Berghuis B, Hussain KH, Duquette RA, Rasau J, Capten J. 2011. Molecular subtype analysis determines the association of advanced breast cancer in Egypt with favorable biology. *Boston Medical Cancer Women's Health*,11:44
- Sanchez AM, Flamini MI, Baldacci E, Goglia L, Genazzani AR, Simoncini T. 2010. Estrogen receptor alpha promotes breast cancer cell motility and invasion via focal adhesion kinase and N-WASP. *Molecular endocrinology*, 24(11):2114-2125
- Sarrio D, Rodrigues-Pinilla SM, Hardisson D, Cano A, Moreno-Bueno G, Palacios J. 2008. Epithelial-Mesenchymal Transition in Breast Cancer Relates to the Basal-like Phenotype. *Cancer Research* :68;989
- Savary K and Moustakas A. 2011. Role of TGF- β signaling in EMT, cancer progression and metastasis. *Drug discovery today: Disease Model*,8:121-126
- Scher HI dan Yagoda A. 1987. Bone metastases: Pathogenesis, treatment and rationale for use of resorption inhibitors. *American Journal of Medicine* 82 (suppl. 2a): 6-27
- Schneider M, Othman-Hassan K, Christ B, Wilting J. 1999. Lymphangioblasts in the avian wing bud. *Development Dynamics*,216:311-9

- Schnitt SJ, Guidi AJ 2000. Pathology of invasive breast cancer. Dalam: Harris JR, Lippmann ME, Morrow M, Osborne CK (eds). *Diseases of the breast*. 2nd eds. Lippincott, Williams & Wilkins, Philadelphia: 425-70
- Schoppmann SF, Schindl M, Breitender-Geleff S, Soleima A, Breitender G, Karner B *et al.*, 2001. Inflammatory stromal reaction correlates with lymphatic microvessel density in early-stage cervical cancer. *Anticancer Research*, 21: 3419-23
- Schoppmann SF, Horvat R, Birner P. 2002. Lymphatic vessels and lymphangiogenesis in female cancer: mechanisms, clinical impact and possible implication for anti-lymphangiogenic therapies (Review). *Oncology Reports*, 9: 455-460
- Schoppmann SF, Bayer G, Aumayr K, Taucher S, Geleff S, Rudas M, Kubista E, Hausmaninger H, Samonigg H, Gnant M, Jakes R, Horvat R. 2004. Prognostic value of lymphangiogenesis and lymphovascular invasion in invasive breast cancer. *Annals of Surgery*, 204: 306-312
- Schoppmann SF, Fenzl A, Nagy K, Unger S, Bayer G, Geleff S, Gnant M, Horvat R, Jakes R, Birner P. 2006. VEGF-C expressing TAMs in lymph node positive breast cancer: impact on lymphangiogenesis and survival. *Surgery* 139: 839-46
- Shayan R, Achen MG, Stacker SA. 2006. Lymphatic vessels in cancer metastasis: bridging the gaps. *Carcinogenesis*, 27 (9): 1729–1738
- Shi X, Xi L, Weng D, Chen G, Song X, Wu P, Wang B, Wei J, Wang S, Zhou J, Ma D. 2008. Clinicopathological significance of VEGF-C, VEGFR-3 and cyclooxygenase-2 in early-stage cervical cancer. *International Journal of Biomedicine*, 4(1): 58-63
- Sheridan C, Kishimoto H, Fuchs RK, Mehrotra S, Bhat-Nakshatri P, Turner CH, Goulet R, Nakshatri H. 2006. CD44 +/ CD24- breast cancer cells exhibit enhanced invasive properties an early step necessary for metastasis. *Breast Cancer Research*, 8: R59
- Siegel R, Naishadham D, Jemal A. 2012. Cancer Statistics. *CA Cancer Journal for Clinicians*. 62(1): 10-29
- Skobe M, Hawighorst T, Jackson DG, Prevo R, Janes L, Velasco P, Riccardi L, Alitalo K, Claffey K, Detmar M. 2001. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. *Nature Medicine*, 7: 192-8
- Song YJ, Shin SH, Cho JS, Park MH, Yoon JH, Jegal YJ. 2011. The Role of Lymphovascular Invasion as a Prognostic Factor in Patients with Lymph Node-Positive Operable Invasive Breast Cancer. *Journal of Breast Cancer*. 14(3): 198–203

- Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johsen H, Pesich R, Geisler S, Demeter J, Perou CM, Lonning PE, Brown PO, Borresen-Dale AL, Botstein D. 2003. Repeated observation of breast tumor subtypes in independent gene expression data sets. *Proceeding of the National Academy of Sciences USA*, 100:8418-23
- Stacker SA, Caesar C, Bakdwin ME, Thorton GE, Williams RA, Prevo R, Jackson DG, Nishikawa S, Kubo H, Aschen MG. 2001. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. *Nature Medicine*, 7(2):186-91
- Su JL, Yang PC, Shih JY *et al.*, 2006. The VEGF-C/Fit-4 axis promotes invasion and metastasis of cancer cells. *Cancer Cell*, 9(209):209-23
- Su Y, Zheng Y, Zheng W, *et al* (2011). Distinct distribution and prognostic significance of molecular subtypes of breast cancer in Chinese women: a population-based cohort study. *BioMed Central Cancer*, 11, 292
- Sundar SS, Ganesan TS, 2007. Role of lymphangiogenesis in cancer. *Journal of Clinical Oncology*, 25(27):4298-4307
- Tammela T, Saaristo A, Holopainen T, Lyytikka J, Kotronen A, Pitkonen M, Abo-Ramadan U, Yla-Herttuala S, Petrova TV, Alitalo K. 2007. Therapeutic differentiation and maturation of lymphatic vessels after lymph node dissection and transplantation. *Nature Medicine* 13: 1458–1466
- Tan PH, Bay BH, Yip G, Selvarajan S, Tan P, Wu J, Lee CH, Li KB, 2005. Immunohistochemical detection of Ki-67 in breast cancer correlates with transcriptional regulation of genes related to apoptosis and cell death. *Modern Pathology*, 18:374-81
- Taneja P, Maglic D, Kai F, Zu S, Kendig RD, Fry EA, Inoue K. 2010. Classical and novel prognostic markers for breast cancer and their clinical significance. *Clinical Medical Insight: Oncology*, 4:15-34
- Takashima T, Onoda N, Ishikawa T, Ogawa Y, Kato Y, Fujimoto Y, Sowa M, Hirakawa K. 2002. Prognostic value of combined estrogen receptor status and cellular proliferation activity in breast cancer patients with extensive lymph node metastasis. *Oncology Report*, 9:589-94
- Talley LI, Grizzle WE, Watebor JW, *et al.* 2002. Hormone receptors and proliferation in breast carcinomas of equivalent histologic grades in pre and postmenopausal women. *International Journal of Cancer*, 98:118-27
- Tavassoli FA, Devilee P. 2003. *WHO Classification of tumours. Pathology and genetics. Tumours of the breast and female genital organs*, IARC Press, Lyon
- Teguh Aryandono, Harijadi, Soeripto. 2006. Breast cancer in young women: Prognostic factors and clinicopathological features. *Asian Pacific Journal of Cancer Prevention*, 7:451-4

- Taixeira C, Reed JC, Pratt MA. 1995. Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells. *Cancer Research*, 55:3902-7
- Teramoto S, Arihiro K, Koseki M, Kataoka T, Asahara T, Ohdan H. 2008, Role of VEGF-c and D mRNA in breast cancer. *Hiroshima Journal of Medical Sciences*, 57(2): 73-8
- Tezuka K, Onoda N, Takashima T, Takagaki K, Ishikawa T, Wakasa T, Wakasa K, Hirakawa K. 2007. Prognostic significance of lymphovascular invasion diagnosed by lymphatic endothelium immunostaining in breast cancer patients. *Oncology Reports*, 17:997-1003
- Timensko AV, Chakraborty C, Wagner GF, Lala PK. 2006. COX-2-mediated stimulation of the lymphangiogenic factor VEGF-C in human breast cancer. *British Journal of Cancer*, 94(8): 1154-1163
- Timoshenko, A. V., Rastogi, S., Lala, P. K. 2007. Investigation promoting role of VEGF-C and VEGF-C binding receptors in human breast cancer cells. *British Journal of Cancer*, 97(8):1090-8
- Tjindarbumi, D. dan Mangunkusumo, R. 2002 Cancer in Indonesia, Present and Future. *Japan Journal of Clinical Oncology* (32) Suppl 1: S17-21
- Toi, M., Bando, H., Ogawa, T., Muta, M., Hornig, C., and Weich, H. A. 2002. Significance of vascular endothelial growth factor (VEGF)/soluble VEGF receptor-1 relationship in breast cancer. *International Journal of Cancer* 98, 14-18.
- Touboul E, Buffat L, Belkacemi Y, *et al.*, 1999. Local recurrence s and distant metastases after breast-conserving surgery and radiation therapy for early breast cancer. *International Journal of Radiation Oncology, Biology, Physics*, 43: 25-38
- UICC, 2002. *TNM classification of malignant tumors*. 6th eds John and Willey & Sons, New York
- Van der Auwera I, Cao Y, Tille JC, Pepper MS, Jackson DG, Fox SB, Harris AL, Dirix LY, Vermeulen PB. 2006. First international consensus on the methodology of lymphangiogenesis quantification in solid human tumours. *British Journal of Cancer*. 95:1611-25
- van Iterson V, Leidenius M, von Smitten K, Bono P, Heikkilä P. 2007. VEGF-D in association with VEGFR-3 promotes nodal metastasis in human invasivelobular breast cancer. *American Journal of Clinical Pathology*. 128(5):759-766
- Valtola R, Salven P, Heikkilä P, Taipale J, Joensuu H, Rehn M, Pihlajaniemi T, Weich H, deWaal R, Aitalo K. 1999. VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. *American Journal of Pathology*, 154(5): 1381-90

- Vleugel MM, Bos R, van der Groep P, Greijer AE, Shvarts A, Stel HV, van der Wall E, van Diest PJ. 2004. Lack of lymphangiogenesis during breast carcinogenesis. *Journal of Clinical Pathology*, 57:746-751
- Voduc KD, Cheang MCU, Tyldesley S, Gelmon K, Nielson TO, Kennecke H. 2010. Breast cancer subtypes and regional relaps. *Journal of Clinical Oncology*, 28(10): 1671-1677
- Vogel CL, Azevedo S, Hilsenbeck S, *et al.*, 1992. Survival after first time recurrence of breast cancer. The Miami experience. *Cancer*, 709:129-35
- Voss MJ, Moller MF, Powe DG, Niggemann B, Zanker KS, Entschladen F. 2011. Luminal and basal-like breast cancer cells show increased migration induced by hypoxia, mediated by an autocrine mechanism. *BioMed Central Cancer* . 11:158
- Wang GS, Zhu H, Jie-Bi S. 2012. Pathological features and prognosis of different molecular subtypes of breast cancer. *Molecular Medicine Reports*, 6: 779-782
- Wang CA, Harrel JC, Iwanaga R, Jedlika P, Ford HL, 2014. VEGF-C promotes breast cancer progression via a novel antioxidant mechanism that involves regulation of superoxide dismutase 3. *Breast Cancer Research*, 16(5): 462
- Waugh DJ, Wilson C 2008. The interleukin-8 pathway in cancer. *Clin Cancer Res*. 14:6735-6741
- Widodo I, Ferronika P, Harijadi A, Triningsih E, Utoro T, Soeripto. 2013. Clinicopathological significance of lymphangiogenesis and tumor lymphovascular invasion in Indonesian breast cancers. *Asia Pacific Journal of Cancer Prevention*, 14(2):997-1001
- Widodo I, KusDwianingsih E, Triningsih E, utoro T, Soeripto. 2014. Clinicopathological features of Indonesian breast cancers with different molecular subtypes. *Asia Pacific Journal of Cancer Prevention*, 15(15):6109-6113
- Wigle JT, Oliver G. 1999. Prox 1 function for the development of the murine lymphatic system. *Cell*, 98(6):769-78
- Witte MH, Jones K, Wilting J, Dictor M, Selg M, Mchale N, Gershenwald JE, Jackson DG. 2006. Structure function relationships in the lymphatic system and implications for cancer biology. *Cancer Metastasis Review*, 25:159-84
- Wo JY, Chen NK, Neville BA, Lin NU, Punglia RS. 2011. Effect of very small tumor size on cancer-specific mortality in node-positive breast cancer. *Journal of Clinical Oncology*, 29:2619- 2627
- Wolff AC, Hammond MEH, Schwartz JN *et al.* 2001. American Society of Clinical Oncology/ College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor 2 testing in breast cancer. *Archives of Pathology and Laboratory Medicine*, 13(1):18-43

- Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hann WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF. 2007. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for human epidermal growth factor receptor2 testing in breast cancer. *Archives Pathology and Laboratory Medicine*,13:21-33
- Wolff AC, Hammond EH, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JMS, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, Press MF, Spears PA, Vance GH, Viale G, Hayes DF. 2013. Recommendation for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/ College of American Pathologists Clinical Practice Guideline Update. *Journal of ClinicalOncology*, 31(31):3997-4013
- Wülfing P, Kersting C, Buerger H, Mattsson B, Mesters R, Gustmann C, Hinrichs B, Tio J, Böcker W, Kiesel L. 2005. Expression patterns of angiogenic and lymphangiogenic factors in ductal breast carcinoma in situ. *British Journal of Cancer*. 92(9):1720– 1728
- Wu Qw, She HQ, Liang J, Huang YF, Yang QM, Yang QL, Zhang ZM. 2012. Expression and clinical significance of extracellular matrix protein 1 and vascular endothelial growth factor-C in lymphatic metastasis of human breast cancer. *BioMed Cancer*. 12:47
- Xie XD, Qu SX, Zheng ZD, Song FL, Liu DW. 2008. Relation of lymphatic microvessel density detected by MoAb D2-40 with VEGF-C expression in breast cancer, *ZhonghuaZhong Liu ZaZhi*, 30(5):356-60
- Yanagawa M, Ikemot K, Kawauchi S, Furuya T, Yamamoto S, Oka M, Oga A, Nagashima Y, Sasaki K. 2012. Luminal A and luminal B (HER2 negative)subtypes of breast cancer consist of a mixture oftumors with different genotype. *British Medical Cancer Research*, 5:376
- Yang XR, Sherman ME, Rimm DL et al., 2007. Differences in risk factors for breast cancer molecular sub-type in a population based study. *Cancer Epidemiology Biomarker and Prevention*,16(3):439-543
- Yang W, Klos K, Yang Y, Smith TL, Shi D, Yu D. 2002. ErbB2 overexpression correlates with increased expression of VEGF A, C and D in human breast carcinoma. *Cancer*,94:2855-61
- Yamauchi C, Hasebe T, Iwasaki M, Imoto S, wada N, Fukayama M, Ichiai A. 2005. Accurate assessment of lymph vessels tumour emboli in invasive ductal carcinoma of the breast according to tumour areas, and their prognostic significance.*HumanPathology*,38:247-59
- Yavuz S, Paydas S, Disel U, Zorludemir S, Erdogan S. 2005. VEGF-C expression in breast cancer: Clinical importance. *Advance in Therapy*,22(4):368-77

- Yilmaz M, Christofori G, Lehenbre F. 2007. Distinct mechanisms of tumor invasion and metastasis. *Trends in molecular Medicine*,13(12):535-41
- Yokoyama Y, Charnock-Jones DS, Licence D. et al., 2003. Vascular endothelial growth factor D is an independent prognostic factor in epithelial ovarian carcinoma. *British Journal of Cancer*,88:237-44
- Yonemura Y, Endou Y, Tabachi K, Kawamura T, Yun HY, Kameya T. 2006. Evaluation of lymphatic invasion in primary gastric cancer by a new monoclonal antibody D2-40. *Human Pathology* ,37: 1193-9
- Yu KD, Jiang YZ, Chen S, Cao ZG, Shen ZZ, Shao ZM. 2012. Effect of Large Tumor Size on Cancer-Specific Mortality in Node-Negative Breast Cancer. *Mayo Clinic Proceedings*. 87(12): 1171–1180
- Zaha DC, Lazar E, Lazureanu C. 2010. Clinicopathologic features and five years survival analysis in molecular subtypes of breast cancer .*Romanian Journal of Morphology and Embryology* . 51(1):85–89
- Zhang XH, Huang DP, Guo GL, Chen GR, Chen G R, Zhang X, Wan L, Chen SY. 2008 Coexpression of VEGF and COX-2 and its association with lymphangiogenesis in human breast cancer. *BioMed Central Cancer*. 8(4):1-8
- Zhao YC, Ni XJ, Li Y, Yuan ZX, Zhu YY, Luo CY. 2012. Peritumoral-lymphangiogenesis induced by vascular endothelial growth factor C and D promotes lymph node metastasis in breast cancer patients. *World Journal of Surgical Oncology*, 10:165